Auris Medical is a biopharmaceutical company focused on developing therapies for unmet medical needs in neurotology and CNS disorders. The company is presently working on intranasal betahistine for the treatment of vertigo and the prevention of antipsychotic-induced weight gain and somnolence. Moreover, it is developing AM-301 for protection against airborne pathogens and allergens. Auris Medical's pipeline includes two Phase 3 programs for acute inner ear hearing loss and acute inner ear tinnitus. Established in 2003, the company is headquartered in Bermuda but operates from Basel, Switzerland. Its shares trade on the NASDAQ Capital Market under the symbol "EARS."